MedTrace Logo

Phase 3 Papulopustular Rosacea Study

NCT01493687 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 683

Last updated 2021-02-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.

Conditions

  • Papulopustular Rosacea (PPR)

Interventions

DRUG

CD5024

CD5024 1% Cream, once daily

DRUG

Azelaic acid 15% Gel

Topical Gel applied twice daily

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Michael Graeber, M.D. · Galderma R&D, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-07-31
Completion
2013-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01493687 on ClinicalTrials.gov